Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus nab-paclitaxel as second-line therapy for advanced pancreatic cancer
NCT03401827Phase 4Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Mar 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of gemcitabine, paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Seoul National University Hospital. Status: unknown.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03401827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03401827.